Subject
Neurology (clinical),Neurology,General Medicine
Reference35 articles.
1. Pharm N. Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MShttps://www.novartis.com/news/media-releases/novartis-data-aan-show-gilenya-first-and-only-disease-modifying-therapy-proven-superiority-versus-glatiramer-acetate-relapsing-remitting-ms20192019.[cited 2019 18 August].
2. Fingolimod: therapeutic mechanisms and ocular adverse effects;Mandal;Eye (Lond),2017
3. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity;Lee;J. Biol. Chem.,2006
4. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis;Zarbin;Ophthalmology,2013
5. Fingolimod and macular edema: pathophysiology, diagnosis, and management;Cugati;Neurol. Clin. Pract.,2014
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献